Proacta Inc.
This article was originally published in Start Up
Executive Summary
Oncology drug developer Proacta Inc. is taking advantage of tumor hypoxia to activate a nontoxic prodrug to a cytotoxic chemotherapeutic. Since the agent acts only in areas of low oxygenation, it is nontoxic to normal tissues.
You may also be interested in...
Start-Up Previews (07/2007)
A preview of the emerging health care companies profiled in the current, all-profiles issue of Start-Up. This month's profile groups are "Start-Ups in Obesity," "New Technologies for Infertility," and "New Zealand Biotech." Plus these Start-Ups Across Health Care: Intelect Medical, N Spine, and Solace Pharmaceuticals.
New Zealand Biotech
The other land down under is getting serious about moving its affordable world-class science to global markets. For start-ups, establishing a US presence may be key. The three NZ start-ups that we profile in this issue--CoDa Therapeutics, Proacta and Protemix--have found their own paths for taking their technologies to the worldwide market via a US presence.
New Zealand Biotech
The other land down under is getting serious about moving its affordable world-class science to global markets. For start-ups, establishing a US presence may be key. The three NZ start-ups that we profile in this issue--CoDa Therapeutics, Proacta and Protemix--have found their own paths for taking their technologies to the worldwide market via a US presence.
Need a specific report? 1000+ reports available
Buy Reports